Clearside Biomedical, Inc.
CLSDQ
$0.95
$0.1215.14%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -59.15% | -78.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -59.15% | -78.88% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -59.15% | -76.37% | |||
| SG&A Expenses | 73.99% | -12.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 78.35% | -46.12% | |||
| Operating Income | -97.31% | 31.45% | |||
| Income Before Tax | -32.86% | 40.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.86% | 45.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.86% | 45.34% | |||
| EBIT | -97.31% | 31.45% | |||
| EBITDA | -99.66% | 31.95% | |||
| EPS Basic | -31.72% | 45.98% | |||
| Normalized Basic EPS | -31.74% | 40.85% | |||
| EPS Diluted | -31.72% | 45.98% | |||
| Normalized Diluted EPS | -31.74% | 40.85% | |||
| Average Basic Shares Outstanding | 0.86% | 1.20% | |||
| Average Diluted Shares Outstanding | 0.86% | 1.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||